⌕
Charles River Laboratories International · CRL · NYSE
Tenet 33 · Weak
Compare
$332.16−1.00%At closeTenet 33 · Weak
$332.16−3.36 (−1.00%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Charles River Laboratories International (CRL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CRL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 17, 2026 · 06:19 ETEARNINGS EXPECTED BY FEB 17
Fifth Third Bancorp Purchases 4,299 Shares of Charles River Laboratories International, Inc. $CRL

Fifth Third Bancorp raised its holdings in Charles River Laboratories International, Inc. (NYSE: CRL) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exc…

CRL −1.0% todayRead at source ↗
● Business WireNov 16, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Charles River Laboratories to Present at Jefferies Global Healthcare Conference

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference.…

CRL −1.0% todayRead at source ↗
● Defense WorldNov 14, 2026 · 03:30 ETEARNINGS EXPECTED BY FEB 17
Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis

Alpha Teknova (NASDAQ: TKNO - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two compa…

CRL −1.0% todayRead at source ↗
● Defense WorldNov 13, 2026 · 03:43 ETEARNINGS EXPECTED BY FEB 17
Commonwealth Equity Services LLC Buys 31,177 Shares of Charles River Laboratories International, Inc. $CRL

Commonwealth Equity Services LLC grew its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 733.4% in a recent quarter, according to the company in its most recent filing with the Securities and Exch…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 12, 2026 · 12:41 ET
GMRS vs. CRL: Which Stock Should Value Investors Buy Now?

Investors interested in Medical Services stocks are likely familiar with GMR Solutions Inc. (GMRS) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck r…

CRL −1.0% todayRead at source ↗
● Business WireNov 12, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River has announced a series of strategic investments and operational enhancements across its global Microbial Solutions network.…

CRL −1.0% todayRead at source ↗
● Defense WorldNov 11, 2026 · 04:02 ETEARNINGS EXPECTED BY FEB 17
5,106 Charles River Laboratories International, Inc. $CRL Shares Purchased by Brighton Jones LLC

Brighton Jones LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 546.1% during a recent quarter, according to its most recent Form 13F filing with the Securities and Ex…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:51 ET
Here's Why Charles River Laboratories (CRL) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 10:16 ET
Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and Prospects

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.…

CRL −1.0% todayRead at source ↗
● Business WireNov 9, 2026 · 06:10 ETCOMPANY'S OWN WORDS
Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses.…

CRL −1.0% todayRead at source ↗
● MarketBeatNov 5, 2026 · 08:17 ETEARNINGS EXPECTED BY FEB 17
Charles River Laboratories International Q3 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL raised its 2026 revenue and earnings outlook after third-quarter organic revenue growth accelerated to 4.7%, supported by demand for safety assessment and manufacturing …

CRL −1.0% todayRead at source ↗
● Defense WorldNov 5, 2026 · 04:00 ETEARNINGS EXPECTED BY FEB 17
Boston Trust Walden Corp Sells 37,537 Shares of Charles River Laboratories International, Inc. $CRL

Boston Trust Walden Corp reduced its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 13.0% during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commissi…

CRL −1.0% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 14:14 ETEARNINGS EXPECTED BY FEB 17
Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript

Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 17
Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises

CRL beats Q3 earnings and revenue estimates as organic growth and margin expansion drive results, prompting the company to raise its 2026 outlook.…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 17
Charles River (CRL) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates a…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 09:11 ETEARNINGS EXPECTED BY FEB 17
Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates

Charles River Laboratories (CRL) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.43 per share a year ago.…

CRL −1.0% todayRead at source ↗
● Business WireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 17
Charles River Laboratories Announces Third-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Third-Quarter 2026 Results.…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 12:41 ETEARNINGS EXPECTED BY FEB 17
Charles River's Q3 Earnings on Deck: What's in Store for the Stock?

CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.…

CRL −1.0% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 17
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

CRL −1.0% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 02:50 ETEARNINGS EXPECTED BY FEB 17
Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Charles River Laboratories advanced during the quarter following a strong earnings report and an increase to full-year guidance. We exited the NCLH position during the quarter and redeployed proceeds into Royal Caribbean…

CRL −1.0% todayRead at source ↗
● Business WireOct 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Charles River Leverages Virtual Control Groups in GLP Studies

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.…

CRL −1.0% todayRead at source ↗
● Defense WorldOct 27, 2026 · 05:50 ET
Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company Stock

Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) Director James Foster sold 24,042 shares of the company's stock in a transaction dated Thursday, October 22nd. The shares were sold at an avera…

CRL −1.0% todayRead at source ↗
● Business WireOct 22, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs.…

CRL −1.0% todayRead at source ↗
● Business WireOct 13, 2026 · 08:00 ET
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to s…

CRL −1.0% todayRead at source ↗
● Business WireOct 9, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 17
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.…

CRL −1.0% todayRead at source ↗
● Business WireOct 6, 2026 · 08:00 ET
Charles River and Autolomous Partner to Transform Laboratory Execution Systems

WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Cha…

CRL −1.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 17. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just CRL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.